$2.56 Billion is the total value of BVF INC/IL's 75 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 21.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GHRS | Buy | GH RESEARCH PLCordinary shares | $204,610,000 | +1.5% | 9,275,158 | +0.0% | 7.98% | +5.7% |
| KYMR | Buy | KYMERA THERAPEUTICS INC | $186,832,000 | +46.4% | 3,180,658 | +20.9% | 7.29% | +52.4% |
| OLMA | OLEMA PHARMACEUTICALS INC | $183,591,000 | -1.5% | 6,661,503 | 0.0% | 7.16% | +2.5% | |
| RCUS | Buy | ARCUS BIOSCIENCES INC | $112,624,000 | +46.6% | 3,229,822 | +15.4% | 4.39% | +52.6% |
| New | MERUS N V | $111,322,000 | – | 5,060,071 | +100.0% | 4.34% | – | |
| ARGX | Sell | ARGENX SEsponsored adr | $110,594,000 | -43.6% | 366,204 | -43.8% | 4.32% | -41.3% |
| RPTX | REPARE THERAPEUTICS INC | $97,676,000 | -15.8% | 3,722,398 | 0.0% | 3.81% | -12.4% | |
| XOMA | XOMA CORP DEL | $87,381,000 | -27.2% | 3,530,543 | 0.0% | 3.41% | -24.2% | |
| PTGX | Buy | PROTAGONIST THERAPEUTICS INC | $69,139,000 | -59.0% | 3,901,759 | +3.9% | 2.70% | -57.3% |
| LXRX | Buy | LEXICON PHARMACEUTICALS INC | $69,072,000 | +79.3% | 14,360,000 | +71.1% | 2.70% | +86.6% |
| RVMD | REVOLUTION MEDICINES INC | $68,364,000 | -13.3% | 2,485,049 | 0.0% | 2.67% | -9.8% | |
| RLAY | Sell | RELAY THERAPEUTICS INC | $64,609,000 | -39.9% | 2,049,113 | -30.3% | 2.52% | -37.4% |
| GLPG | New | GALAPAGOS NVspon adr | $58,909,000 | – | 1,119,733 | +100.0% | 2.30% | – |
| AMRN | Buy | AMARIN CORP PLCspons adr new | $58,177,000 | +674.0% | 11,407,182 | +564.8% | 2.27% | +705.0% |
| FDMT | 4D MOLECULAR THERAPEUTICS IN | $54,098,000 | +12.0% | 2,005,862 | 0.0% | 2.11% | +16.6% | |
| SNDX | SYNDAX PHARMACEUTICALS INC | $47,516,000 | +11.3% | 2,486,429 | 0.0% | 1.85% | +15.9% | |
| ACIU | Sell | AC IMMUNE SA | $46,535,000 | -31.3% | 6,935,179 | -18.8% | 1.82% | -28.5% |
| VSTM | Buy | VERASTEM INC | $46,130,000 | +0.4% | 14,977,258 | +32.7% | 1.80% | +4.5% |
| RAIN | Buy | RAIN THERAPEUTICS INC | $44,249,000 | +46.3% | 2,957,807 | +52.0% | 1.73% | +52.3% |
| New | AADI BIOSCIENCES INC | $33,689,000 | – | 1,147,052 | +100.0% | 1.31% | – | |
| SPRO | Sell | SPERO THERAPEUTICS INC | $33,310,000 | +11.6% | 1,809,352 | -15.4% | 1.30% | +16.2% |
| KURA | KURA ONCOLOGY INC | $30,626,000 | -10.2% | 1,635,112 | 0.0% | 1.20% | -6.5% | |
| New | TYRA BIOSCIENCES INC | $29,814,000 | – | 1,694,933 | +100.0% | 1.16% | – | |
| INFI | INFINITY PHARMACEUTICALS INC | $28,672,000 | +14.4% | 8,383,645 | 0.0% | 1.12% | +19.2% | |
| PIRS | PIERIS PHARMACEUTICALS INC | $27,547,000 | +35.0% | 5,328,239 | 0.0% | 1.08% | +40.5% | |
| REPL | Buy | REPLIMUNE GROUP INC | $27,462,000 | -22.2% | 926,529 | +0.8% | 1.07% | -19.0% |
| CTIC | CTI BIOPHARMA CORP | $26,343,000 | +18.0% | 8,929,690 | 0.0% | 1.03% | +22.8% | |
| VIRX | VIRACTA THERAPEUTICS INC | $24,815,000 | -29.3% | 3,094,174 | 0.0% | 0.97% | -26.4% | |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $24,715,000 | +40.7% | 1,373,044 | +37.3% | 0.96% | +46.5% |
| XENE | XENON PHARMACEUTICALS INC | $24,017,000 | -17.9% | 1,571,778 | 0.0% | 0.94% | -14.6% | |
| IKNA | Buy | IKENA ONCOLOGY INC | $23,121,000 | -6.8% | 1,832,071 | +3.7% | 0.90% | -3.0% |
| EPIX | Buy | ESSA PHARMA INC | $22,812,000 | -67.4% | 2,851,461 | +16.3% | 0.89% | -66.1% |
| OVID | OVID THERAPEUTICS INC | $22,280,000 | -14.1% | 6,631,051 | 0.0% | 0.87% | -10.6% | |
| JANX | Sell | JANUX THERAPEUTICS INC | $22,005,000 | -25.0% | 1,017,314 | -13.5% | 0.86% | -21.9% |
| PNT | New | POINT BIOPHARMA GLOBAL INC | $21,318,000 | – | 2,772,226 | +100.0% | 0.83% | – |
| GLYC | GLYCOMIMETICS INC | $20,902,000 | -5.6% | 9,544,262 | 0.0% | 0.82% | -1.8% | |
| NGM | NGM BIOPHARMACEUTICALS INC | $20,074,000 | +6.6% | 955,000 | 0.0% | 0.78% | +10.9% | |
| CRNX | Buy | CRINETICS PHARMACEUTICALS IN | $20,079,000 | +4284.1% | 953,879 | +3828.7% | 0.78% | +4505.9% |
| DAWN | Sell | DAY ONE BIOPHARMACEUTICALS I | $19,228,000 | -8.1% | 810,284 | -11.8% | 0.75% | -4.3% |
| MTEM | MOLECULAR TEMPLATES INC | $19,168,000 | -14.2% | 2,856,599 | 0.0% | 0.75% | -10.6% | |
| ALPN | New | ALPINE IMMUNE SCIENCES INC | $16,960,000 | – | 1,589,495 | +100.0% | 0.66% | – |
| CGEM | CULLINAN ONCOLOGY INC | $16,591,000 | -12.4% | 735,106 | 0.0% | 0.65% | -8.7% | |
| GRTS | Sell | GRITSTONE BIO INC | $16,503,000 | -1.0% | 1,528,072 | -16.3% | 0.64% | +3.0% |
| CALA | Buy | CALITHERA BIOSCIENCES INC | $16,246,000 | +6.5% | 7,452,331 | +2.1% | 0.63% | +10.8% |
| CALT | CALLIDITAS THERAPEUTICS ABsponsered ads | $16,215,000 | -26.6% | 750,000 | 0.0% | 0.63% | -23.6% | |
| CFRX | CONTRAFECT CORP | $16,088,000 | -8.0% | 3,972,300 | 0.0% | 0.63% | -4.1% | |
| STRO | SUTRO BIOPHARMA INC | $15,619,000 | +1.6% | 826,825 | 0.0% | 0.61% | +5.7% | |
| SLN | SILENCE THERAPEUTICS PLCads | $14,413,000 | -15.3% | 666,666 | 0.0% | 0.56% | -11.8% | |
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $13,228,000 | +106.6% | 804,126 | +129.7% | 0.52% | +115.0% |
| COGT | COGENT BIOSCIENCES | $12,886,000 | +3.7% | 1,532,282 | 0.0% | 0.50% | +7.9% | |
| ELEV | Buy | ELEVATION ONCOLOGY INC | $12,388,000 | -42.6% | 1,590,298 | +0.0% | 0.48% | -40.3% |
| CDTX | Buy | CIDARA THERAPEUTICS INC | $10,700,000 | +21.9% | 4,776,904 | +9.9% | 0.42% | +26.7% |
| ANGN | Buy | ANGION BIOMEDICA CORP | $10,467,000 | -22.4% | 1,071,297 | +3.4% | 0.41% | -19.4% |
| New | NUVALENT INC | $10,114,000 | – | 448,512 | +100.0% | 0.40% | – | |
| MEIP | MEI PHARMA INC | $9,748,000 | -3.2% | 3,532,057 | 0.0% | 0.38% | +0.8% | |
| ANAB | Sell | ANAPTYSBIO INC | $9,069,000 | -56.8% | 334,398 | -58.7% | 0.35% | -55.0% |
| MIRM | New | MIRUM PHARMACEUTICALS INC | $8,684,000 | – | 435,936 | +100.0% | 0.34% | – |
| ELDN | Buy | ELEDON PHARMACEUTICALS INC | $8,426,000 | -4.3% | 1,363,435 | +22.5% | 0.33% | -0.3% |
| MOLN | New | MOLECULAR PARTNERS AGads | $8,267,000 | – | 419,008 | +100.0% | 0.32% | – |
| GNCA | GENOCEA BIOSCIENCES INC | $7,704,000 | -17.9% | 4,012,404 | 0.0% | 0.30% | -14.5% | |
| IVA | Buy | INVENTIVA SAads | $7,705,000 | +429.6% | 544,500 | +408.9% | 0.30% | +447.3% |
| ERYP | ERYTECH PHARMAsponsored adr | $7,586,000 | +19.0% | 1,314,656 | 0.0% | 0.30% | +23.8% | |
| CRVS | Sell | CORVUS PHARMACEUTICALS INC | $6,635,000 | -32.4% | 1,370,947 | -62.7% | 0.26% | -29.6% |
| ALRN | AILERON THERAPEUTICS INC | $5,371,000 | -18.4% | 5,265,555 | 0.0% | 0.21% | -15.0% | |
| GLMD | GALMED PHARMACEUTICALS LTD | $5,021,000 | -8.2% | 1,799,694 | 0.0% | 0.20% | -4.4% | |
| EUCRU | EUCRATES BIOMEDICAL ACQU CORunit 10/23/2027 | $4,955,000 | -2.7% | 500,000 | 0.0% | 0.19% | +1.0% | |
| FLACU | FRAZIER LIFESCIENCES ACQU COunit 12/09/2025 | $4,930,000 | -2.2% | 500,000 | 0.0% | 0.19% | +1.6% | |
| FVAM | 5 01 ACQUISITION CORP | $4,900,000 | -1.7% | 500,000 | 0.0% | 0.19% | +2.1% | |
| RACB | RESEARCH ALLIANCE CORP II | $4,830,000 | -3.4% | 500,000 | 0.0% | 0.19% | +0.5% | |
| XFOR | X4 PHARMACEUTICALS INC | $4,485,000 | -18.6% | 847,879 | 0.0% | 0.18% | -15.5% | |
| ABOS | New | ACUMEN PHARMACEUTICALS INC | $4,304,000 | – | 289,663 | +100.0% | 0.17% | – |
| FWP | Sell | FORWARD PHARMA A/Ssponsord ads new | $2,987,000 | -34.3% | 432,892 | -18.1% | 0.12% | -31.2% |
| JYAC | JIYA ACQUISITION CORP | $2,934,000 | -1.6% | 300,000 | 0.0% | 0.11% | +1.8% | |
| RZLT | REZOLUTE INC | $1,416,000 | -48.0% | 190,815 | 0.0% | 0.06% | -46.1% | |
| SELB | Sell | SELECTA BIOSCIENCES INC | $1,330,000 | -81.2% | 319,678 | -81.1% | 0.05% | -80.4% |
| CNTA | Exit | CENTESSA PHARMACEUTICALS PLCsponsored ads | $0 | – | -58,900 | -100.0% | -0.05% | – |
| IMVT | Exit | IMMUNOVANT INC | $0 | – | -1,273,516 | -100.0% | -0.50% | – |
| FBRX | Exit | FORTE BIOSCIENCES INC | $0 | – | -591,811 | -100.0% | -0.75% | – |
| RACA | Exit | THERAPEUTICS ACQUISITION COR | $0 | – | -2,772,226 | -100.0% | -1.07% | – |
| MRUS | Exit | MERUS N V | $0 | – | -7,285,071 | -100.0% | -5.75% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
| 13F-HR | 2023-11-14 |
| 3 | 2023-11-13 |
| 3 | 2023-11-06 |
| 4 | 2023-11-06 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.